Standard Biotools (LAB) Free Cash Flow Growth (1y) (2011 - 2026)
Standard Biotools (LAB) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.67 Bn | 194.07 Bn | 7.27 Bn | 28.87% |
| 2 | Stryker | 129.56 Bn | 126.09 Bn | 4.50 Bn | 14.12% |
| 3 | Medtronic | 119.87 Bn | 110.65 Bn | 6.41 Bn | 0.77% |
| 4 | Boston Scientific | 73.80 Bn | 73.27 Bn | 3.85 Bn | 13.29% |
| 5 | Edwards Lifesciences | 52.66 Bn | 48.41 Bn | 1.35 Bn | 142.84% |
| 6 | Dexcom | 34.56 Bn | 32.61 Bn | 830.00 Mn | -11.68% |
| 7 | GE HealthCare Technologies | 34.16 Bn | 32.05 Bn | 2.18 Bn | 750.00% |
| 8 | Koninklijke Philips | 26.44 Bn | 23.12 Bn | 4.55 Bn | 0.40% |
| 9 | Steris | 23.23 Bn | 22.75 Bn | 684.20 Mn | -14.34% |
| 10 | Standard Biotools | 258.10 Mn | -218.62 Mn | 10.54 Mn | 52.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.76% |
| Mar 31, 2026 | -32.77% |
| Dec 31, 2025 | 82.51% |
| Sep 30, 2025 | 32.54% |
| Jun 30, 2025 | 58.72% |
| Mar 31, 2025 | 44.14% |
| Dec 31, 2024 | 3.61% |
| Sep 30, 2024 | -166.64% |
| Jun 30, 2024 | -276.40% |
| Mar 31, 2024 | -566.21% |
| Dec 31, 2023 | 43.28% |
| Sep 30, 2023 | 52.40% |
| Jun 30, 2023 | 67.12% |
| Mar 31, 2023 | 42.31% |
| Dec 31, 2022 | -3,887.20% |
| Sep 30, 2022 | 48.10% |
| Jun 30, 2022 | 20.01% |
| Mar 31, 2022 | 16.98% |
| Dec 31, 2021 | 96.54% |
| Sep 30, 2021 | -909.72% |